KR880010775A - 면역글로로불린 결합체 - Google Patents

면역글로로불린 결합체 Download PDF

Info

Publication number
KR880010775A
KR880010775A KR1019880002464A KR880002464A KR880010775A KR 880010775 A KR880010775 A KR 880010775A KR 1019880002464 A KR1019880002464 A KR 1019880002464A KR 880002464 A KR880002464 A KR 880002464A KR 880010775 A KR880010775 A KR 880010775A
Authority
KR
South Korea
Prior art keywords
conjugate
monoclonal antibody
ida
fragment
antibody
Prior art date
Application number
KR1019880002464A
Other languages
English (en)
Other versions
KR0130906B1 (ko
Inventor
화큐하르 캠프벨 멕켄지 아이언
알란 피터즈 지오프레이
존 스미드 마크
Original Assignee
원본 미기재
팜이탈리아 카롤로 에르바 에스·알·엘
더 유니버시티 오브멜보른
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본 미기재, 팜이탈리아 카롤로 에르바 에스·알·엘, 더 유니버시티 오브멜보른 filed Critical 원본 미기재
Publication of KR880010775A publication Critical patent/KR880010775A/ko
Application granted granted Critical
Publication of KR0130906B1 publication Critical patent/KR0130906B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

면역글로로불린 결합체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 안트라사이클린 유도체의 구조를 도시한 것이다. 제2도는 안티-Ly-2.1(0.5mg)에 대한 이다루비신(Ida)의 커플링을 도시한 것이다. 제 3도는 ITT(1) 75 NS E3 표적 세포상에서의 안티-Ly-2.1 결합체의 항체 희석도(X 10-1) (가로좌표)에 대한 % 로제트 형성세포(세로좌표)로서 측정한 항체 역가를 도시한 것이다.

Claims (10)

  1. 모노클로날 항체, 또는 항체의 항원 결합 부위 적어도 하나늘 함유하는 모노클로날 항체의 단편에 결합된 이다루비신(Ida)으로 이루어짐을 특징으로 하는 면역글로불린 결합체.
  2. 제 1항에 있어서, 모노클로날 항체 또는 이의 단편이 목적하는 표적 조직에 대해 특이적인 결합체.
  3. 제 2항에 있어서, 표적 조직이 인체에 신생물인 결합체
  4. 제 1항에 있어서, 모노클로날 항체 또는 이의 단편이 「임파구 세포표면 항원에 대해 특이적인 결합체」.
  5. 제 1 내지 4항 중 어느 한 항에 있어서, 각각의 항체 분자에 2내지 8개의 Ida 분자가 공유적으로 결합된 결합체.
  6. 제 1내지 5항 중 어느 한 항에 있어서, Ida가 Ida의 C-14 위치에서 모노클로날 항체 또는 항체 단편에 결합된 결합체.
  7. Ida를 모노클로날 항체 또는 이의 단편에 결합시킴을 특징으로하여, 제 1내지 6항 중 어느 한 항에서 청구된 면역글로불린 결합체를 제조하는 방법.
  8. 제 7항에 있어서, 14-할로-Ida를 모노클로날 항체 또는 이의 단편과 반응시키는 방법.
  9. 약제학적으로 허용되는 담체 또는 희석제 및, 활성성분으로서, 제 1내지 6항중의 어느 한항에서 청구되거나 또는 제 7 또는 8항에서 청구된 방법에 의해 제조된 면역글로불린 결합체를 함유함을 특징으로 하는 약제학적 조성물.
  10. 세포를 제 1항에 청구된 면역글로불린 결합체(이 결합체 중의 모노클로날 항체 또는 이의 단편은 고갈시킬 임파구상에 존재하는 세포 표면 항원에 대해 특이적이다)와 함께 시험관내에서 배양함을 특징으로 하여, 세포의 집단으로부터「임파구의 서브세트」를 특이적으로 고갈시키는 방법.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019880002464A 1987-03-11 1988-03-10 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 KR0130906B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPI080387 1987-03-11
AUPI0803 1987-03-11
AUPI295587 1987-07-07
AUPI2955 1987-07-07

Publications (2)

Publication Number Publication Date
KR880010775A true KR880010775A (ko) 1988-10-24
KR0130906B1 KR0130906B1 (ko) 1998-04-23

Family

ID=25643244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002464A KR0130906B1 (ko) 1987-03-11 1988-03-10 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (29)

Country Link
US (1) US5798097A (ko)
JP (1) JP2736255B2 (ko)
KR (1) KR0130906B1 (ko)
CN (1) CN1045621C (ko)
AT (1) AT395375B (ko)
AU (1) AU622105B2 (ko)
BE (1) BE1001051A4 (ko)
CA (1) CA1329156C (ko)
CH (1) CH678815A5 (ko)
CZ (1) CZ281193B6 (ko)
DE (1) DE3808166C2 (ko)
DK (1) DK173792B1 (ko)
ES (1) ES2006109A6 (ko)
FI (1) FI98706C (ko)
FR (1) FR2612074B1 (ko)
GB (1) GB2203154B (ko)
GR (1) GR1000059B (ko)
HU (1) HU205266B (ko)
IE (1) IE64781B1 (ko)
IL (1) IL85688A0 (ko)
IT (1) IT8819746A0 (ko)
MY (1) MY103231A (ko)
NL (1) NL8800610A (ko)
NO (1) NO178954C (ko)
NZ (1) NZ223834A (ko)
PT (1) PT86960B (ko)
RU (1) RU2106147C1 (ko)
SE (1) SE503402C2 (ko)
YU (1) YU46858B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
ES2357406T3 (es) * 1998-10-09 2011-04-26 Vegenics Limited Flt4 (VEGFR-3) COMO DIANA PARA LA OBTENCIÓN DE IMÁGENES DE TUMORES Y TERAPIA ANTITUMORAL.
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
WO2004094647A2 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
US20080108138A1 (en) * 2006-06-13 2008-05-08 Vermette Patrick Bioactive compositions and their use in cell patterning
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
RU2699007C2 (ru) 2013-02-18 2019-09-02 Ведженикс Пти Лимитед Молекулы, связывающие лиганды, и их применение

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1500421A (en) * 1975-01-22 1978-02-08 Farmaceutici Italia Optically active anthracyclinones
AT346838B (de) * 1975-01-22 1978-11-27 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
AT343811B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
AT343812B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven daunosaminylderivaten von anthracyclinonen
GB1511680A (en) 1975-11-18 1978-05-24 Farmaceutici Italia Daunosaminyl anthracyclinones
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
GB8413464D0 (en) * 1984-05-25 1984-07-04 Erba Farmitalia Anthracycline-anionic polymer conjugates
JPS61155334A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造方法
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant

Also Published As

Publication number Publication date
AT395375B (de) 1992-12-10
DK131588D0 (da) 1988-03-11
CZ161288A3 (en) 1996-07-17
HU205266B (en) 1992-04-28
BE1001051A4 (fr) 1989-06-20
NL195078C (ko) 2003-07-30
PT86960A (pt) 1988-04-01
FI881158A (fi) 1988-09-12
GR880100148A (en) 1989-01-31
NO178954B (no) 1996-04-01
US5798097A (en) 1998-08-25
NO178954C (no) 1996-07-10
FI98706B (fi) 1997-04-30
JP2736255B2 (ja) 1998-04-02
ATA67488A (de) 1992-05-15
IL85688A0 (en) 1988-08-31
YU48288A (en) 1989-08-31
MY103231A (en) 1993-05-29
GB2203154A (en) 1988-10-12
CH678815A5 (ko) 1991-11-15
FI98706C (fi) 1997-08-11
NZ223834A (en) 1990-05-28
DE3808166C2 (de) 1997-08-28
RU2106147C1 (ru) 1998-03-10
JPS63301832A (ja) 1988-12-08
SE503402C2 (sv) 1996-06-10
NO881105L (no) 1988-09-12
NL8800610A (nl) 1988-10-03
CN88101810A (zh) 1988-11-09
DK131588A (da) 1988-09-12
GB2203154B (en) 1991-06-26
SE8800886D0 (sv) 1988-03-11
CZ281193B6 (cs) 1996-07-17
CN1045621C (zh) 1999-10-13
PT86960B (pt) 1992-06-30
IE64781B1 (en) 1995-09-06
ES2006109A6 (es) 1989-04-01
FR2612074B1 (fr) 1991-06-21
IT8819746A0 (it) 1988-03-11
FR2612074A1 (fr) 1988-09-16
AU622105B2 (en) 1992-04-02
CA1329156C (en) 1994-05-03
IE880701L (en) 1988-09-11
KR0130906B1 (ko) 1998-04-23
HUT46547A (en) 1988-11-28
NO881105D0 (no) 1988-03-11
DE3808166A1 (de) 1988-09-22
GB8805865D0 (en) 1988-04-13
DK173792B1 (da) 2001-11-05
SE8800886L (sv) 1989-09-12
AU1288188A (en) 1988-09-15
GR1000059B (el) 1990-06-27
FI881158A0 (fi) 1988-03-11
YU46858B (sh) 1994-06-24

Similar Documents

Publication Publication Date Title
CA1064826A (en) Antigen binding dimer bound to drug
US4906452A (en) Trichothecene conjugates and methods of use
Raso et al. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen
US4565696A (en) Production of immunogens by antigen conjugation to liposomes
KR860001803B1 (ko) 이뮤노톡신 결합체의 제조방법
Huang et al. Characterization of antibody covalently coupled to liposomes
WO1983001571A1 (en) Liposome conjugates and diagnostic methods therewith
US4263279A (en) Pharmaceutically active compositions containing adriamycin and daunomycin
JPH02152993A (ja) アンチマーおよびアンチマー複合体
KR880010775A (ko) 면역글로로불린 결합체
KR880007531A (ko) 면역글로불린 결합체
US7964415B2 (en) Stable water-soluble polyethylenimine conjugates and methods of use thereof
Chu et al. Ethylenediamine modified bovine serum albumin as protein carrier in the production of antibody against mycotoxins
Agodoa et al. Precipitating antigen-antibody systems are required for the formation of subepithelial electron-dense immune deposits in rat glomeruli.
CA1224718A (en) Anti-cancer drugs comprising platinum complexes
Hubbard et al. Localization of halothane-induced antigen in situ by specific anti-halothane metabolite antibodies.
Kulkarni et al. Conjugation of methotrexate to IgG antibodies and their F (ab) 2 fragments and the effect of conjugated methotrexate on tumor growth in vivo
Watts In situ 125I‐labelling of endosome proteins with lactoperoxidase conjugates.
Breukels et al. Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide
Zara et al. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation
Celada et al. An in vitro immuno-enzymatic assay of tumor antigens in the mouse with β-galactosidase
Persiani et al. In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma
US20230364257A1 (en) Antibody conjugate and method for enhancing immune effect function of antibody molecule
RU95104325A (ru) Коньюгаты антител с улучшенными свойствами
AU6248894A (en) Coupling method using selective amination of maleimide

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

Free format text: TRIAL NUMBER: 1996201001948; APPEAL AGAINST DECISION TO DECLINE REFUSAL

N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101029

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee